Understanding and Comparing Ionizing Radiation Doses to Patients

By Paul C. Johns, PhD, FCCPM

This article gives an introduction of the quantities and units used in ionizing radiation and of the biological effects. Background radiation provides, on average, 2.4 mSv of effective dose per year. Medical procedures provide effective doses ranging from less than a day's worth of background for bone densitometry via dual-energy x-ray absorptiometry to more than four years' worth for coronary angiography and more than eight years' worth for angioplasty. Since imaging with ionizing radiation involves using a known carcinogen, all procedures carry risk both to patients and to personnel. Only procedures that will provide information useful for patient care should be done, and the benefit to risk ratio must be optimized through quality assurance of the equipment and good judgement of the operator.

Une présentation est donnée des quantités et des unités utilisées en rayonnement ionisant, ainsi que des effets biologiques. Le rayonnement de fond procure, en moyenne, 2,4 mSv de dose effective par année. Les procédures médicales prévoient des doses effectives équivalant à moins d'une journée de rayonnement de fond pour la densitométrie osseuse par voie d'absorptométrie à rayons X en double énergie; ces doses peuvent varier également jusqu'à plus de quatre ans pour la coronarographie et de huit ans pour l'angioplastie. Comme l'imagerie au moyen du rayonnement ionisant suppose l'utilisation d'un cancérogène connu, toutes les procédures comportent un risque pour les patients et le personnel. Seules les procédures qui donnent lieu à une information pertinente pour les soins à donner aux patients devraient être effectuées, et le rapport bénéfice/risque devrait être optimalisé par l'assurance de la qualité de l'équipement et le bon jugement de l'opérateur.

Introduction

he field of ionizing radiation dosimetry and our understanding of radiation risk continue to evolve. They are particularly relevant to those who work in radiology or nuclear medicine facilities, and to their patients.

Patients often ask such questions as:

After an x-ray exam, will I be radioactive? The quick and easy answer is "no". The photon energies used in radiology are far too low to convert stable atomic nuclei into radioactive nuclei. (The threshold required is several MeV, whereas the photons in radiology are below 150 keV). Once the x-ray machine is turned off, the radiation is gone — just

as light from an electric lamp stops the moment it is switched off.

Is there a safe level of radiation dose? This one is not as easy to answer, and in fact is open to controversy. Life on this planet has developed in the presence of natural background radiation. Our cells contain machinery that repairs the damage done by ionizing radiation. At the same time, we know that at doses higher than those used in radiology, radiation leads to cancer, and other adverse effects. At present the scientific consensus is to assume that the probability of cancer is proportional to the total dose. Diagnostic imaging examinations should be ordered after considered judgement that the risk from ionizing radiation is outweighed by the benefits gained from the

information about the disease and/or its treatment. This overview should provide the reader with some perspective on the magnitude of the radiation doses in medical imaging, and how these compare with each other and with background. In the following section, an introduction is given to the means by which radiation affects living systems. The radiation quantities and their units are then described, and values are given for the background radiation dose rate. Current estimates of the doses in health care procedures are given. Means of reducing the risks for patients and staff are discussed.

Radiation Interactions in Living Systems

The amount of *energy* carried by x- or gamma (γ) rays in medicine is very small. To illustrate this, consider that a whole body x- or - γ ray dose of 3 to 5 Gray (Gy) will cause about 50 per cent of the people irradiated to die within 60 days.² Yet a dose of 5 Gy leads to a temperature rise of only 0.0012 °C in water. Clearly, heating due to energy absorption is not the cause of the biological effect.

Quantity	SI Unit	Old Unit
Quantity	Si Umi	Old Ollit
Dose (<i>D</i>)	Gray (Gy)	rad
D = energy/mass	1 Gy = 1 J kg ⁻¹	1 rad = 0.01 Gy
Equivalent Dose (<i>H</i>)	Sievert (Sv)	rem
$H = w_R D$		1 rem = 0.01 Sv
Effective Dose (E)	Sievert (Sv)	rem
$E = \sum w_T H_T$		New York
Exposure (X)	Coulomb kg ⁻¹ (C kg ⁻¹)	Roentgen (R)
X = charge/mass of air		$1 R = 2.58 \times 10^{-4} C kg^{-1}$
Air Kerma (<i>K</i> _{c,air})	J kg ⁻¹ or Gy	Roentgen (R)
$K_{c,air} = energy/mass of air$		$1 R = 8.76 \times 10^{-3} J kg^{-1}$
Activity (A)	Becquerel (Bq)	Curie (Ci)
A = number of decays/time	1 Bq = 1 decay s^{-1}	$1 \text{ Ci} = 3.70 \times 10^{10} \text{ Bq}$

Table 2. Tissue Weighting Factors for the Calculation of Effective Dose^a

Tissue or Organ	Tissue Weighting Factor, w _T
Gonads	0.20
Bone marrow (red)	0.12
Colon	0.12
Lung	0.12
Stomach	0.12
Bladder	0.05
Breast	0.05
Liver	0.05
Esophagus	0.05
.Thyroid	0.05
Skin	0.01
Bone surface	0.01
Remainder ^{b,c}	0.05

- a) data from Reference no. 4
- b) The remainder consists of: adrenals, brain, upper large intestine, small intestine, kidney, muscle, pan creas, spleen, thymus, uterus.
- c) In those exceptional cases in which a single one of the remainder tissues or organs receives an equivalent dose in excess of the highest dose in any of the 12 organs for which a weighting factor is specified, a weighting factor of 0.025 should be applied to that tissue or organ and a weighting factor of 0.025 to the average dose in the remainder as defined above.

Photon interactions in tissue via the photoelectric effect, Compton scattering, or (in the case of radiotherapy) pair production, lead to energetic electrons that expend their energy in the tissue. These supply enough energy to liberate electrons from several atoms, leaving the atoms in a charged state. In water, which is the principal component of tissue, this leads to formation of the hydroxyl

(•OH) radical, which is a very reactive chemical species. (The little dot in the chemical symbol •OH indicates an unpaired electron, which makes the chemical entity highly reactive). The •OH attacks other molecules through oxidation, and this in turn can change their biological function. Of utmost importance is the effect of radical damage to the DNA of the cell, which regulates the cell's function. Living organisms have evolved systems that attempt to repair this damage, and the effect of the radiation depends on how much damage is not repaired or is mis-repaired.

Ionizing radiation, then, mostly affects living systems indirectly through chemical and biological means. The amount of radiation, the rate at which it is delivered, whether it is delivered at once or in several fractions, whether the tissue has a ready supply of oxygen or not — all these affect the outcome. The field of radiobiology was developed largely to exploit the dependence on these parameters in order to make radiotherapy more effective. In what follows, these factors are ignored for simplicity, but it must be recognized that the risk from ionizing radiation is much more complicated than is presented below.

Ionizing Radiation Quantities and Units

There are several quantities used in the science of ionizing radiation (Table 1). The current international consensus on the system of quantities and units is given in Report 60 of the International Commission on Radiological Protection (ICRP).¹ This superseded the previous consensus in an earlier report.³ The ICRP-60 terminology and occupational dose limit recommendations are now being adopted by national regulatory bodies.

Dose (D): This is the energy absorbed by a material per unit mass. The SI unit is the Gray (Gy), with 1 Gy corresponding to 1 J of energy absorbed per kg of material. The old unit was the rad; 1 Gy equals 100 rads.

Equivalent Dose (H): Not all types of ionizing radiation have the same biological effect. For example, to achieve a given amount of cell killing with a beam of protons requires only 1/5 the dose as with a beam of x rays. Equivalent dose puts such differing beams on the same basis. It is calculated as the product of a radiation weighting factor, w_R (previously³ called "quality factor"), which depends on the type and energy of radiation, and the dose:

$$H = w_R D.$$

The SI unit is the Sievert (Sv). It has replaced the old unit, the rem; 1 Sv is equal to 100 rem. For photon beams and for electron beams, w_R is 1, so that a dose of 1 Gy gives an equivalent dose of 1 Sv. This conveniently covers all beams used in diagnostic radiology and in most radiotherapy clinics, but it must be remembered that for other types of radiation, a different conversion is used. For example, a dose of 1 Gy gives an equivalent dose of 5 Sv for protons, and 20 Sv for alpha (α) particles.

Effective Dose (E): There is less risk from partial irradiation of the body than from whole-body irradiation. Furthermore the different tissues of the body have different radiosensitivities. For example, bone marrow is much more sensitive than the extremities. To account for this, the effective dose E (previously³ called "effective dose equivalent", with symbol $H_{\rm E}$) is calculated by summing over the tissues or organs in the body the product of a tissue weighting factor, $w_{\rm T}$, and the equivalent dose $H_{\rm T}$ to the tissue:

$$E = \sum w_T H_T$$

The weighting factors¹ were obtained by analysis of the detriment to an individual due to doses to the different organs, where "detriment" includes both fatal and non-fatal cancers, hereditary effects passed to subsequent generations, and length of life lost.

Table 2 lists the weighting factors w_T specified by ICRP-60.⁴ Their sum is 1, so that for whole-body irradiation in which each organ receives, for example, an equivalent dose of 2 Sv, the effective dose is also 2 Sv.

Exposure (X): This is the quantity that is most easily measured, but it is also the least directly connected to patient risk. It arises from the prevalence of air ionization chambers to measure radiation fields. The historical unit is the Roentgen (R); an exposure of 1 R corresponds to 2.58 x 10⁻⁴ Coulombs of charge liberated per kg of air. Under the SI system, there is no special unit, and exposures are reported in units of C kg⁻¹. Exposure is a property of the beam itself, and does not directly describe its effect on tissue. To an accuracy of about 20%, however, a beam which gives an exposure of 1 R will give a dose to soft tissue of about 0.01 Gy (1 rad).

Air Kerma $(K_{c,air})$: This quantity is replacing exposure as a way of describing the incident beam in terms of its interaction with air. It is the energy transferred from the photon beam per unit mass of air. The SI unit is the J kg⁻¹. The Gy is also commonly used.

Activity (A): This quantity specifies the amount of a radioactive substance. Activity is the average number of nuclei decaying per unit of time. Under the SI system, the unit of activity is the Becquerel (Bq), with 1 Bq being 1 decay per second. The historical unit was the Curie (Ci). This was originally chosen as the activity of 1 gram of radium, but today, it is fixed as exactly 3.70 x 10¹⁰ Bq.

Background Radiation

Life has evolved in the presence of "natural" or "background" radiation. Table 3 gives typical values for the annual background, composed of cosmic rays, cosmogenic radionuclides, and terrestrial radiation.⁵

The atmosphere largely shields us from cosmic rays, and regions of higher elevation have larger annual effective doses. For example, at sea level the cosmic ray background is approximately 0.27 mSv per year, while in Mexico City⁶ (elevation 2240 m) it is 0.82 mSv y⁻¹. In Table 3, an average value of 0.38 mSv y⁻¹ is taken. Cosmogenic radionuclides are those produced on the planet by cosmic ray interactions, principally in the

W. Jak	
Source	Annual Effectiv
	Dose (mSv)
Cosmic rays	0.38
Cosmogenic	0.01
radionuclides	
Terrestrial radiation	
External exposure	0.46
Internal exposure,	0.23
excluding radon	
Internal exposure,	1.3
from radon and its	
progeny	
Total 2	2.4 mSv per year
Effective dose rate from	n
cosmic rays:	
DMRAN DELET	0.003 mSv per hou
commercial	
air flight	

atmosphere. The most important is ¹⁴C. On average everyone ingests about 20 kBq of 14C annually, leading to an annual effective dose of 0.01 mSv.⁷ Terrestrial radiation is that produced by radionuclides whose half lives are comparable to the age of the earth, most importantly 40K, and the heavy isotopes ²³²Th and ²³⁸U, and their decay series of unstable nuclides. The most important of these are the short lived progeny of ²²²Rn, which is a descendant of ²³⁸U. Since radon is a noble gas, it does not combine easily with other elements, and therefore percolates out of soil where it is formed by radioactive decay. Its concentration in air is highly variable, and depends on location and the local geology. The choice of materials used in a building, and its ventilation system design, will both influence the concentration within. On average, it is estimated to give over half the background dose rate, or 1.3 mSv y⁻¹.

The average background effective dose rate of 2.4 mSv y^1 could also be expressed as 0.00027 mSv h^{-1} . Table 3 notes that the rate is increased about ten times on a commercial air flight. This is due to the increased cosmic ray intensity.

Risks Due to Ionizing Radiation

The biological effects of ionizing radiation can be put into two categories: stochastic and deterministic. Stochastic effects occur randomly. The possible effects are carcinogenesis and the induction of genetic effects, passed on to the progeny of irradiated individuals. The current scientific consensus is that the probability is proportional to the equivalent dose to the organ, with no threshold. The data are based on incidents which have given people doses generally higher than those found in medicine. Analysis of cancer incidence in Japanese atomic bomb survivors is the principal source of data. Reference 8 provides a useful summary of the data sources.

Deterministic effects are not random, but occur whenever some threshold is exceeded. They include the growth of cataracts in the eye, and skin erythema. The threshold for cataracts is generally a dose to the lens of somewhat under 2 Gy for single exposures.⁹ The threshold for skin erythema is a skin dose of about 2 to 5 Gy, depending on individual sensitivity.¹⁰

Typical Radiation Doses to Patients

A recent report¹¹ for the Atomic Energy Control Board (AECB) determined that 892 medical x-ray procedures per 1000 population are done annually in Canada, or almost one procedure for each person in the country. These deliver, on average, an additional 0.94 mSv effective dose to each and every Canadian annually. In addition, nuclear medicine procedures deliver a per capita effective dose of 0.16 mSv annually. Together, the additional effective dose of 1.1 mSv is 46% of the average annual natural background.

Approximate effective doses from different health care procedures are shown in Table 4. These are all for adults. The effective doses vary over several orders of magnitude. Extremity and dental x-rays are low-dose procedures, principally because they involve radiologically thin regions of the body. Dual-energy x-ray aborptiometry (DEXA) also delivers low doses, because it generates only a relatively crude, low-resolution image. The higher-dose procedures usually involve several minutes, or

Pr	ocedure <i>E</i> , Effec	ctive Dose (mSv)
Rā	idiological X-Ray Procedures	
	ctremity ^{a,j}	0.06
	iest ^{a,j}	0.14
Sk	.ull ^{a,j}	0.16
	ımbosacral spine ^{a,j}	1.7
Ma	ammogram ^b	0.3
	pper GI ^c	6.7
	rebral angiography ^d	7.0
	ronary angiography	11.
P1	'CA (percutaneous transluminal	20.
	coronary angioplasty) ^e	
Co	mputed Tomography (CT) scan of	abdomen¹ 3.9
	one Mineral Densitometry	
	ıal energy x-ray absorptiometry (D	0.0025
D€	ental X-Ray Procedures	
	ll mouth exam ^h	0.08
	50mm : Barrier St. 1	0.007
LU	noramic ^h	0.007
		0.001
Νι	ıclear Medicine Procedures	
Ni Th	uclear Medicine Procedures Lyroid ^{i.j} (250 MBq ^{99m} Tc pertechneta	ate) 3.8
Nu Th Liv	ıclear Medicine Procedures yroid ^{i,j} (250 MBq ^{99m} Tc pertechneta ver/spleen ^{i,j} (117 MBq ^{99m} Tc colloid)	ate) 3.8) 1.6
Nu Th Liv Bo	uclear Medicine Procedures Lyroid ^{i,j} (250 MBq ^{99m} Tc pertechneta ver/spleen ^{i,j} (117 MBq ^{99m} Tc colloid) one scan ^{i,j} (790 MBq ^{99m} Tc phosphat	ate) 3.8) 1.6 te) 6.3
Nu Th Liv Bo	ıclear Medicine Procedures yroid ^{i,j} (250 MBq ^{99m} Tc pertechneta ver/spleen ^{i,j} (117 MBq ^{99m} Tc colloid)	ate) 3.8) 1.6 te) 6.3
Nu Th Liv Bo Ca	aclear Medicine Procedures Lyroid ^{i,j} (250 MBq ^{99m} Tc pertechneta ver/spleen ^{i,j} (117 MBq ^{99m} Tc colloid) one scan ^{i,j} (790 MBq ^{99m} Tc phosphat rdiovascular ^{i,j} (76 MBq ²⁰¹ Tl chlorid data from Reference no. 12	ate) 3.8) 1.6 te) 6.3 le) 17.5
Nu Th Liv Bo Ca	iclear Medicine Procedures Lyroid ^{i,j} (250 MBq ^{99m} Tc pertechneta ver/spleen ^{i,j} (117 MBq ^{99m} Tc colloid) one scan ^{i,j} (790 MBq ^{99m} Tc phosphat rdiovascular ^{i,j} (76 MBq ²⁰¹ Tl chloric data from Reference no. 12 estimated using a mean glandular dose to be	ate) 3.8) 1.6 te) 6.3 le) 17.5
Nu Th Liv Bo Ca	aclear Medicine Procedures Lyroid ^{i,j} (250 MBq ^{99m} Tc pertechneta ver/spleen ^{i,j} (117 MBq ^{99m} Tc colloid) one scan ^{i,j} (790 MBq ^{99m} Tc phosphat rdiovascular ^{i,j} (76 MBq ²⁰¹ Tl chloric data from Reference no. 12 estimated using a mean glandular dose to be mGy from a two-view per breast examinatio	ate) 3.8) 1.6 te) 6.3 le) 17.5 oth breasts of 3.0 on. It is assumed
Nu Th Liv Bo	Iclear Medicine Procedures Lyroid ^{i,j} (250 MBq ^{99m} Tc pertechneta Lyroid ^{i,j} (250 MBq ^{99m} Tc pertechneta Lyroid ^{i,j} (117 MBq ^{99m} Tc colloid) Lyroidene scan ^{i,j} (790 MBq ^{99m} Tc phosphat Lyroidene scan ^{i,j} (76 MBq ²⁰¹ Tl chlorid Lyroidene data from Reference no. 12 Lyroidene estimated using a mean glandular dose to be Lyroidene mGy from a two-view per breast examinatio Lyroidene that negligible dose is delivered to other organical	ate) 3.8) 1.6 te) 6.3 le) 17.5 oth breasts of 3.0 on. It is assumed ans by scattered radiation.
Nu Th Liv Bo Ca	Iclear Medicine Procedures Lyroid ^{i,j} (250 MBq ^{99m} Tc pertechneta Ver/spleen ^{i,j} (117 MBq ^{99m} Tc colloid) Vene scan ^{i,j} (790 MBq ^{99m} Tc phosphate Trdiovascular ^{i,j} (76 MBq ²⁰¹ Tl chloric Adata from Reference no. 12 estimated using a mean glandular dose to be mGy from a two-view per breast examination that negligible dose is delivered to other organ Since the weighting factor of 0.05 given in 19	ate) 3.8) 1.6 te) 6.3 le) 17.5 oth breasts of 3.0 on. It is assumed ans by scattered radiation.
Nu Th Liv Bo Ca	Iclear Medicine Procedures Lyroid ^{i,j} (250 MBq ^{99m} Tc pertechneta Ver/spleen ^{i,j} (117 MBq ^{99m} Tc colloid) One scan ^{i,j} (790 MBq ^{99m} Tc phosphat Irdiovascular ^{i,j} (76 MBq ²⁰¹ Tl chloric data from Reference no. 12 estimated using a mean glandular dose to be mGy from a two-view per breast examinatio that negligible dose is delivered to other organ Since the weighting factor of 0.05 given in To population average over both sexes, it is down	ate) 3.8) 1.6 te) 6.3 de) 17.5 oth breasts of 3.0 on. It is assumed ans by scattered radiation. Table 2 is for the ubled here in calculating
Nu Th Liv Bo Ca	Iclear Medicine Procedures Lyroid ^{i,j} (250 MBq ^{99m} Tc pertechneta ver/spleen ^{i,j} (117 MBq ^{99m} Tc colloid) one scan ^{i,j} (790 MBq ^{99m} Tc phosphat rdiovascular ^{i,j} (76 MBq ²⁰¹ Tl chloric data from Reference no. 12 estimated using a mean glandular dose to be mGy from a two-view per breast examinatio that negligible dose is delivered to other orga- Since the weighting factor of 0.05 given in 1 population average over both sexes, it is dow the effective dose to women. Hence 3.0 mSv	ate) 3.8) 1.6 te) 6.3 de) 17.5 oth breasts of 3.0 on. It is assumed ans by scattered radiation. Table 2 is for the ubled here in calculating
Nu Th Liv Bo Ca (a)	Iclear Medicine Procedures Lyroid ^{i,j} (250 MBq ^{99m} Tc pertechneta ver/spleen ^{i,j} (117 MBq ^{99m} Tc colloid) one scan ^{i,j} (790 MBq ^{99m} Tc phosphat rdiovascular ^{i,j} (76 MBq ²⁰¹ Tl chloric data from Reference no. 12 estimated using a mean glandular dose to be mGy from a two-view per breast examinatio that negligible dose is delivered to other orga Since the weighting factor of 0.05 given in 1 population average over both sexes, it is dou the effective dose to women. Hence 3.0 mSv effective dose.	ate) 3.8) 1.6 te) 6.3 de) 17.5 oth breasts of 3.0 on. It is assumed ans by scattered radiation. Table 2 is for the ubled here in calculating
Nu Th Liv Bo Ca (a)	Iclear Medicine Procedures Lyroid ^{i,j} (250 MBq ^{99m} Tc pertechneta ver/spleen ^{i,j} (117 MBq ^{99m} Tc colloid) one scan ^{i,j} (790 MBq ^{99m} Tc phosphat rdiovascular ^{i,j} (76 MBq ²⁰¹ Tl chloric data from Reference no. 12 estimated using a mean glandular dose to be mGy from a two-view per breast examinatio that negligible dose is delivered to other orga Since the weighting factor of 0.05 given in 1 population average over both sexes, it is dow the effective dose to women. Hence 3.0 mSv effective dose. from Reference no.13	ate) 3.8) 1.6 te) 6.3 de) 17.5 oth breasts of 3.0 on. It is assumed ans by scattered radiation. Table 2 is for the ubled here in calculating
Nu Th Liv Bo Ca a) b)	Iclear Medicine Procedures Lyroid ^{i,j} (250 MBq ^{99m} Tc pertechneta Ver/spleen ^{i,j} (117 MBq ^{99m} Tc colloid) Vene scan ^{i,j} (790 MBq ^{99m} Tc phosphate Trdiovascular ^{i,j} (76 MBq ²⁰¹ Tl chloric data from Reference no. 12 estimated using a mean glandular dose to be mGy from a two-view per breast examination that negligible dose is delivered to other organ Since the weighting factor of 0.05 given in The population average over both sexes, it is down the effective dose to women. Hence 3.0 mSv effective dose. from Reference no.13 from Reference no.14	ate) 3.8) 1.6 te) 6.3 le) 17.5 oth breasts of 3.0 on. It is assumed ans by scattered radiation. Table 2 is for the ubled here in calculating $x 0.05 \times 2 = 0.3 \text{ mSV}$
Nu Th Liv Bo Ca a) b)	Iclear Medicine Procedures Lyroid ^{i,j} (250 MBq ^{99m} Tc pertechneta Ver/spleen ^{i,j} (117 MBq ^{99m} Tc colloid) One scan ^{i,j} (790 MBq ^{99m} Tc phosphate Irdiovascular ^{i,j} (76 MBq ²⁰¹ Tl chloric data from Reference no. 12 estimated using a mean glandular dose to be mGy from a two-view per breast examination that negligible dose is delivered to other orgate Since the weighting factor of 0.05 given in The population average over both sexes, it is does the effective dose to women. Hence 3.0 mSv effective dose. from Reference no.13 from Reference no.14 from Reference no.15. E for PTCA calculated	ate) 3.8) 1.6 te) 6.3 de) 17.5 oth breasts of 3.0 on. It is assumed ans by scattered radiation. Table 2 is for the ubled here in calculating $x 0.05 \times 2 = 0.3 \text{ mSv}$
Nu Th Liv Bo Ca a) b)	Iclear Medicine Procedures Lyroid ^{i,j} (250 MBq ^{99m} Tc pertechneta Ver/spleen ^{i,j} (117 MBq ^{99m} Tc colloid) Vene scan ^{i,j} (790 MBq ^{99m} Tc phosphate Trdiovascular ^{i,j} (76 MBq ²⁰¹ Tl chloric data from Reference no. 12 estimated using a mean glandular dose to be mGy from a two-view per breast examination that negligible dose is delivered to other organ Since the weighting factor of 0.05 given in The population average over both sexes, it is down the effective dose to women. Hence 3.0 mSv effective dose. from Reference no.13 from Reference no.14	ate) 3.8) 1.6 te) 6.3 de) 17.5 oth breasts of 3.0 on. It is assumed ans by scattered radiation. Table 2 is for the abled here in calculating $x 0.05 \times 2 = 0.3 \text{ mSv}$ of from the organ doses of an doses not available. Value
Nu Th Liv Bo Ca a) b) c) d) e)	Iclear Medicine Procedures Lyroid ^{i,j} (250 MBq ^{99m} Tc pertechneta Ver/spleen ^{i,j} (117 MBq ^{99m} Tc colloid) One scan ^{i,j} (790 MBq ^{99m} Tc phosphate Indiovascular ^{i,j} (76 MBq ²⁰¹ Tl chloric data from Reference no. 12 estimated using a mean glandular dose to be mGy from a two-view per breast examination that negligible dose is delivered to other orgate Since the weighting factor of 0.05 given in The population average over both sexes, it is down the effective dose to women. Hence 3.0 mSv effective dose. from Reference no.13 from Reference no.15. E for PTCA calculated Ref. 16, then rounded up to account for organ	ate) 3.8) 1.6 te) 6.3 de) 17.5 oth breasts of 3.0 on. It is assumed ans by scattered radiation. Table 2 is for the abled here in calculating $x 0.05 \times 2 = 0.3 \text{ mSv}$ of from the organ doses of an doses not available. Value
Nu Th Liv Bo Ca a) b)	Iclear Medicine Procedures Lyroid ^{i,j} (250 MBq ^{99m} Tc pertechneta ver/spleen ^{i,j} (117 MBq ^{99m} Tc colloid) one scan ^{i,j} (790 MBq ^{99m} Tc phosphate rdiovascular ^{i,j} (76 MBq ²⁰¹ Tl chloric data from Reference no. 12 estimated using a mean glandular dose to be mGy from a two-view per breast examinatio that negligible dose is delivered to other orgat Since the weighting factor of 0.05 given in 12 population average over both sexes, it is down the effective dose to women. Hence 3.0 mSv effective dose. from Reference no.13 from Reference no.14 from Reference no.15. E for PTCA calculated Ref. 16, then rounded up to account for orgat for angiography obtained by scaling the PTCA	ate) 3.8) 1.6 te) 6.3 de) 17.5 oth breasts of 3.0 on. It is assumed ans by scattered radiation. Table 2 is for the abled here in calculating $x 0.05 \times 2 = 0.3 \text{ mSv}$ of from the organ doses of an doses not available. Value
Nu Th Liv Bo Ca a) b) c) d) e)	aclear Medicine Procedures Ayroid ^{i,j} (250 MBq ^{99m} Tc pertechneta Ver/spleen ^{i,j} (117 MBq ^{99m} Tc colloid) One scan ^{i,j} (790 MBq ^{99m} Tc phosphate rdiovascular ^{i,j} (76 MBq ²⁰¹ Tl chloric data from Reference no. 12 estimated using a mean glandular dose to be mGy from a two-view per breast examination that negligible dose is delivered to other orgate Since the weighting factor of 0.05 given in 11 population average over both sexes, it is down the effective dose to women. Hence 3.0 mSv effective dose. from Reference no.13 from Reference no.14 from Reference no.15. E for PTCA calculated Ref. 16, then rounded up to account for orgate for angiography obtained by scaling the PTCA from Reference no.17	ate) 3.8) 1.6 te) 6.3 de) 17.5 oth breasts of 3.0 on. It is assumed ans by scattered radiation. Table 2 is for the abled here in calculating $x 0.05 \times 2 = 0.3 \text{ mSV}$ of from the organ doses of an doses not available. Value
Nu Th Liv Bo Ca a) b)	Iclear Medicine Procedures Lyroid ^{i,j} (250 MBq ^{99m} Tc pertechneta ver/spleen ^{i,j} (117 MBq ^{99m} Tc colloid) one scan ^{i,j} (790 MBq ^{99m} Tc phosphate rdiovascular ^{i,j} (76 MBq ²⁰¹ Tl chloric data from Reference no. 12 estimated using a mean glandular dose to be mGy from a two-view per breast examination that negligible dose is delivered to other orgate Since the weighting factor of 0.05 given in 12 population average over both sexes, it is down the effective dose to women. Hence 3.0 mSv effective dose, from Reference no.13 from Reference no.15. E for PTCA calculated Ref. 16, then rounded up to account for orgate for angiography obtained by scaling the PTCA from Reference no.17 from Reference no.18	ate) 3.8) 1.6 te) 6.3 de) 17.5 oth breasts of 3.0 on. It is assumed ans by scattered radiation. Table 2 is for the abled here in calculating $x 0.05 \times 2 = 0.3 \text{ mSV}$ of from the organ doses of an doses not available. Value

tens of minutes, of fluoroscopy, plus numerous high quality film or digital images. For example, it was found that for upper GI, an average of 4.1 minutes of fluoroscopy were used, while for coronary angiography, 5.4 minutes were required. For angioplasty, 18.7 minutes were required. Typically, fluoroscopic systems deliver a few R min⁻¹ to the patient's skin; typical entrance exposure rates, free in air, were found to be 5.0 R min⁻¹ (44 mJ kg⁻¹ min⁻¹ or 44 mGy min⁻¹) for upper GI exams.

The effective doses in Table 4 should not be mistaken for average organ doses, entrance air kerma, or exposure values. For example, for coronary angiography, the effective dose is estimated to be 11 mSv. However, the average entrance air kerma without backscatter, including all fluoroscopy and cineradiography, was 620 mJ kg⁻¹ (or the entrance exposure was 70 R). Multiplying estimates of entrance exposure by values for the average organ dose per unit entrance exposure calculated using the Monte Carlo photon transport technique for various views,22 the equivalent dose to bone marrow is estimated to be 13 mSv, to lungs 53 mSv, and so on. These values are averages over the entire organ or tissue type in the body, and yield the effective dose when weighted according to Table 2, then summed. The effective dose is smaller than the individual organ doses or entrance air kerma because it is an estimate of the whole body dose that would cause the same detriment.

In terms of period of annual background for the same effective dose, the procedures in Table 4 range from less than a day for DEXA through 9 days for extremity x ray to over four years for coronary angiography. For angioplasty, which is a therapeutic procedure, the background equivalent exceeds eight years. But these comparisons underestimate the equivalent amount of background, because of dose rate effects. A dose over a long time at a low rate is less harmful than the same dose over a short time at a high rate. This is

because in the former case, the cell's radiation repair mechanism has less damage to deal with at a given time.

In radiotherapy, doses several orders of magnitude higher are delivered *to the target tissue*. Summed over many fractions that are given daily over several weeks, the total target dose is as high as 60 Gy. The concept of effective dose does not apply here, in part because the doses are higher than the range over which it can be assumed that the response is linear with dose, and because the short life expectancy of the patients invalidates the tissue weighting factors.

Risk versus Benefit

Although stochastic effects are the main concern in irradiation of patients, deterministic effects have also been seen, particularly skin damage in lengthy and involved interventional procedures.^{23,24} Here education of users is important.

The professional standard is to maximize the benefit/risk ratio. For example, Reference 25 provides an analysis of the tradeoff between finding cancers earlier through mammographic screening versus the statistical risk of inducing cancer by the radiation dose from the exam. In angioplasty, it was estimated that the statistical risk of inducing a fatal cancer by the radiation of the exam was 8 x 10⁻⁴. While this is high enough to be of serious concern, the risk of the alternatives — no intervention, or bypass surgery — is greater, making coronary angioplasty worthwhile.

The Ontario Healing Arts Radiation Protection (HARP) Guidelines²⁶ provide a useful discussion of the ALARA ("As Low As Reasonably Achievable") principle as applied to medical diagnostic imaging. There must be an optimum struck between radiation doses that are subject to ALARA, and image quality that is As High As Reasonably Achievable.

Work remains to be done in this area. As an example, note that standard practice in screen-film radiography is for larger patients to receive both higher kV and higher mAs. However, it has been pointed out that in CT one kilovoltage is commonly used independent of patient size, and that the adjustment in mAs is not large. As a result, although the effective dose for abdominal CT is 3.9 mSv for adults, it is 6.1 mSv for children, and even higher for newborns. On top of this, the risk of carcinogenesis is greater in children than in adults. It is suggested that CT users and manufacturers begin to adjust the kV and mAs according to patient size to reduce the effective dose to children and small adults.

Methods of Risk Reduction

Patient dose can be minimized as follows:

- Take only the number of images needed. Minimize the number of films and/or digital acquisitions, the fluoroscopic time, cineradiographic or digital frame rate and duration, or number of CT slices consistent with adequate information.
- Ensure that only the anatomy of interest is irradiated. This also helps maintain image quality, since larger irradiated volumes generate more scattered radiation, which reduces image quality. In addition, scatter from the patient is the main source of radiation dose to personnel in the procedure room. The beam should always be collimated as tightly as is reasonable. A positive beam limitation device should always be adjusted to just slightly smaller than the image receptor area in use. The zoom magnification of an image intensifier should be consitent with the anatomy of interest. In a cardiac room, use the iris collimation.

- Optimize the generator technique factors. If the kV is too low, there is inadequate penetration; if too high, iodine or barium contrast is lost. Filtration should be sufficient to stop the low-energy photons which otherwise would contribute to dose but would not penetrate the patient to contribute to the image. The patient exposure rate for fluoroscopy must be optimized consistent with an acceptable image noise level.
- Maintain equipment to achieve minimum radiation dose consistent with good image quality. This necessitates a continuing quality control program, qualified service personnel, and good communications. Merely meeting regulatory entrance exposure limits is not enough.

All of the above also benefit in-room personnel. In addition, in an interventional room, it is usually worthwhile to install overhead and under-couch

Employment Opportunity

Vancouver, BC Opportunity

Busy X-Ray clinic, located in the downtown Vancouver area, specializing in Mammography has two career opportunities available:

X-Ray Technician

X-Ray Technician with Mammography experience requird for full-time position.

Ultrasound Technician

Ultrasound Technician required for full-time Breast Imaging postition.

Send resume to:

Suite #505-750 West Broadway St. Vancouver BC V5Z 1H4 Attention: Office Manager

or

Fax: 604-879-4147

x-ray barriers to reduce the scattered radiation to the personnel. Permanent x-ray barriers shield radiation at the source. Their benefit is shared by all personnel. Protective glasses are recommended to personnel for whom the annual eye dose is significant.

Conclusions

The current scientific consensus is that all dose levels of ionizing radiation have some detrimental effect. At the same time, procedures in radiology and nuclear medicine are capable of providing vital information to physicians for diagnosis or for treating disease. It is therefore crucial to optimize the examination.

The Canadian Association of Radiologists has stated²⁷ that: (i), no diagnostic procedure using ionizing radiation should be adopted unless its introduction provides positive net benefits, (ii) exposures should be kept as low as reasonably achievable

(ALARA) with the procedure optimized to reduce the radiation hazard, and (iii) the entrance exposure levels set out in statutory regulations must not be exceeded.

In addition, any reduction in patient dose will reduce the dose to in-room personnel and will prolong the life of the equipment.

Paul Johns received a BASc in Engineering Science and MSc and PhD degrees in Medical Biophysics from the University of Toronto. He has been a reactor safety analyst at Atomic Energy of Canada Limited, radiological physicist at the Ottawa Civic Hospital, and for the last 10 years has been a faculty member in Physics at Carleton University. He is Director of the Ottawa Medical Physics Institute (OMPI), and is a former Chair of the Canadian Organization of Medical Physicists (COMP). His research interests are in the physics of medical x-ray imaging.

Employment Opportunity

MEDICAL RADIOLOGICAL TECHNICIAN

Full time Medical Radiological Technician required immediately for private Diagnostic Imaging group in Edmonton, Alberta Canada.

Successful applicant must be a member in good standing with CAMRT. Mammography experience an asset.

Competitive salary and attractive benefits package offered.

Applicants are requested to forward resume to:

Attention: Sharon Gray Supervisor, Human Resources FAX: (780) 426-2295

EMAIL: SGray@MIC.ab.ca <mailto:SGray@MIC.ab.ca>

Phone: (780) 426-1121

Only successful applicants contacted

References

- International Commission on Radiological Protection (ICRP) Publication 60. 1990 Recommendations of the International Commission on Radiological Protection. Oxford: Pergamon Press, 1991.
- 2. ICRP-60. Annex B, para B, p.39.
- 3. International Commission on Radiological Protection (ICRP) Publication 26. Recommendations of the International Commission on Radiological Protection. Oxford: Pergamon Press, 1977.
- 4. ICRP-60. Table 2, p.8.
- 5. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR),1993 Report to the General Assembly. Sources and effects of ionizing radiation. New York: United Nations, 1993: Annex A, Table 28, p.74, and para 36 p.39.
- 6. UNSCEAR 1993 Report, Annex A, Table 2, p.62.
- 7. UNSCEAR 1993 Report, Annex A. Table 3. p.62.
- 8. Shapiro J. Radiation protection. A guide for scientists and physicians, 3rd ed. Cambridge, Massachusetts: Harvard University Press, 1990: Table 6.2.
- 9. Hall EJ. Radiobiology for the radiologist. 3rd ed. Philadelphia: JB Lippincott Co., 1988: Chapter 18.
- 10. Maxfield WS, Hanks GE, Pizzarello DJ, Blackwell LH. Acute radiation syndrome. In: Dalrymple GV, Gaulden ME, Kollmorgen GM, Vogel HH Jr, eds. Medical radiation biology. Philadelphia: WB Saunders Co., 1973:190-197.
- Atomic Energy Control Board, Advisory Committee on Radiological Protection Report 9. Radiation doses from medical diagnostic procedures in Canada. Aldrich JE, Lentle BC, and Vo C. AECB, Report INFO-0670, Ottawa, March 1997.
- 12. UNSCEAR 1993 Report, Annex C, Table 11, p.295.
- 13. Geleijns J, Broerse JJ, Chandie Shaw MP, Schultz FW, Teeuwisse W, van Unnik JG, and Zoetelief J. A comparison of patient dose for examinations of the upper gastrointestinal tract at 11 conventional and digital x-ray units in The Netherlands. Br J Radiol. 1998;71:745-753.
- 14. McParland BJ. A study of patient radiation doses in interventional radiological procedures. Br J Radiol. 1998;71:175-185.

- 15. Johns PC and Renaud L. Radiation risk associated with PTCA. Primary Cardiology 1994;20(12),27-31.
- 16. Pattee PL, Johns PC, Chambers RJ. Radiation risk to patients from percutaneous transluminal coronary angioplasty. J Am College Cardiology. 1993;22:1044-1051.
- 17. Ware DE, Huda W, Mergo PJ, and Litwiller AL. Radiation effective doses to patients undergoing abdominal CT examinations. Radiology. 1999:210:645-650.
- 18. Huda W and Morin RL. Patient doses in bone mineral densitometry. Br J Radiol. 1996; 69:422-425.
- 19. Suleiman OH, Conway BJ, Quinn P, Antonsen RG, Rueter FG, Slayton RJ, and Spelic DC. Nationwide survey of fluoroscopy: Radiation dose and image quality. Radiology.1997;203:471-476. Erratum: 1998;207:278.
- 20. UNSCEAR 1993 Report, Annex C, para 106, p.239
- 21. UNSCEAR 1993 Report, Annex C, Table 31, p.323
- 22. Gorson RO, Lassen M, Rosenstein M. Patient Dosimetry in Diagnostic Radiology. In: Waggener RG, Kereiakes JG, Shalek RJ, eds. CRC Handbook of medical physics, Vol. 2. Boca Raton, Florida: CRC Press, 1984;467-526.
- 23. Huda W and Peters KR. Radiation-induced temporary epilation after a neuroradiologically guided embolization procedure. Radiology. 1994;193:642-644.
- 24. Shope TB. Radiation-induced skin injuries from fluoroscopy. Radiographics. 1996;16:1195-1199. Also Radiology. 1995;197(P):209 (abstract) and 1995;197(P):449 (abstract). [Presentations at 1995 conference of the RSNA, Chicago].
- 25. Feig SA and Hendrick RE. Risk, benefit, and Controversies in Mammographic Screening. pp. 121-137 in Syllabus: a categorical course in physics. Technical aspects of breast imaging, 3rd edition. edited by Haus AG and Yaffe MJ. RSNA Categorical Course in Physics, 1994.
- 26. The Healing Arts Radiation Protection Guidelines, edited by Yaffe MJ. Ministry of Health, Ontario, 1987.
- 27. Stolberg HO, Hynes DM, Rainbow AJ, and Moran LA. Requesting diagnostic imaging examinations: a position paper of the Canadian Association of Radiologists. J Can Assoc Radiol. 1997;48:89-91.

Notice to Mammography Students

Please note that the telephone number below for ordering the Handbook of Mammography, by S.M. Long, is incorrect as published in the Fall 1999 Professional Development Correspondence Courses brochure. On page 5 of the brochure, the correct telephone number for Shirley M. Long, at Mammography Consultant Services, is 780-462-2615. We regret any inconvenience caused by the misprint.

Avis aux étudiants en mammographie

Si vous prévoyez commander le *Handbook of Mammography?* de S.M. Long, veuillez prendre note qu'il y a une erreur dans le numéro de téléphone publié dans la brochure Cours de perfectionnement professionnel par correspondance (1999). Le numéro de téléphone de Shirley M. Long, chez Mammography Consultant Services, est le **780-462-2615**. Nous regrettons toute complication pouvant découler de cette erreur typographique.